Migraine in Multiple Sclerosis

International Review of Neurobiology

Volumn 79, Issue , 2007, Pages 281-302

  Elliott, Debra G ^a  

^a Louisiana State University Health Sciences Center at Shreveport   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON;

HEADACHE; HUMAN; METABOLISM; MIGRAINE; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW;

HEADACHE; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MIGRAINE DISORDERS; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION;

EID: 34248682938     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(07)79012-8     Document Type: Review

References (130)

1. Aktas O., Prozorovski T., and Zipp F. Death ligands and autoimmune dysfunction. Neuroscientist 12 (2006) 305-316
2. Al-Twaijri W.A., and Shevell M.I. Pediatric migraine equivalents: Occurrence and clinical features in practice. Pediatr. Neurol. 26 (2002) 365-368
3. Alvarez-Lafuente R., De Las Heras V., Bartolome M., Garcia-Montojo M., and Arroyo R. Human herpesvirus 6 and multiple sclerosis: A one-year follow-up study. Brain Pathol. 16 (2006) 20-27
4. Alviggi C., Carrieri P.B., Pivonello R., Scarano V., Pezzella M., De Placido G., Colao A., and Matarese G. Association of pelvic endometriosis with alopecia universalis, autoimmune thyroiditis and multiple sclerosis. J. Endocrinol. Invest. 29 (2006) 182-189
5. Bain V.G., Kaita K.D., Yoshida E.M., Swain E.J., Heathcote M.G., Neumann A.U., Fiscella M., Yu R., Osborn B.L., Cronin P.W., Freimuth W.W., McHutchison J.G., et al. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J. Hepatol. 44 (2006) 671-678
6. Balan V., Nelson D.R., Sulkowski M.S., Everson G.T., Lambiase L.R., Wiesner R.H., Dickson R.C., Post A.B., Redfield R.R., Davis A.U., Neumann B.L., Osborn G.L., et al. A phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir. Ther. 11 (2006) 35-45
7. Banwell B., Reder A.T., Krupp L., Tenembaum S., Eraksoy M., Alexey B., Pohl D., Freedman M., Schelensky L., and Antonijevic I. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurologyy 66 (2006) 472-476
8. Bartolini M., Baruffaldi R., Paolino I., and Silvestrini M. Cerebral blood flow changes in the different phases of migraine. Funct. Neurol. 20 (2005) 209-211
9. Bekieslińska-Figatowska M. T2-hyperintense foci on brain MR imaging. Med. Sci. Monit. 10 Suppl. 3 (2004) 80-87
10. Bowsher D. The management of central post-stroke pain. Postgrad. Med. J. 71 (1995) 598-604
11. Bowsher D. Central pain: Clinical and physiological characteristics. J. Neurol. Neurosurg. Psychiatry 61 (1996) 62-69
12. Bräu N., Bini E.J., Stancic S., Finch D.A., and Aytaman A. Severe migraine headaches are caused by ribavirin but not by interferon α-2B in combination therapy for chronic hepatitis C. J. Hepatol. 38 (2003) 871-872
13. Buzzi M.G., and Moskowitz M.A. The pathophysiology of migraine: Year 2005. J. Headache Pain 6 (2005) 105-111
14. Buzzi M.G., Moskowitz M.A., Shimizu T., and Heath H.H. Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology 30 (1991) 1193-1200
15. Carmosino M.J., Brousseau K.M., Arciniegas D.B., and Corboy J.R. Initial evaluations for multiple sclerosis in a university multiple sclerosis center. Arch. Neurol. 62 (2005) 585-590
16. Chapman J., Rand J.H., Brey R.L., Levine S.R., Blatt I., Khamashta M.A., and Shoenfeld Y. Non-stroke neurological syndromes associated with antiphospholipid antibodies: Evaluation of clinical and experimental studies. Lupus 12 (2003) 514-517
17. Charlier C., Nunes H., Trinchet J.C., Roullet E., Mouthon L., Beaugrand M., and Valeyre D. Evolution of previous sarcoidosis under type 1 interferons given for severe associated disease. Eur. Respir. J. 25 (2005) 570-573
18. Chrisopherson K., and Hromas R. Chemokine regulation of normal and pathologic immune responses. Stem Cells 19 (2001) 388-396
19. Cook S.D. Does Epstein-barr virus cause multiple sclerosis?. Rev. Neurol. Dis. 1 (2004) 115-123
20. Cooney B.S., Grossman R.I., Farber R.E., Goin J.E., and Galetta S.L. Frequency of magnetic resonance imaging abnormalities in patients with migraine. Headache 36 (1996) 616-621
21. Crawford S.G., Kaplan B.J., and Kinsbourne M. Are families of children with reading difficulties at risk for immune disorders and nonrighthandedness?. Cortex 30 (1994) 281-292
22. Cunha F.Q., Poole S., Lorenzetti B.B., and Ferreira S.H. The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia. Br. J. Pharmacol. 107 (1992) 660-664
23. D'Amico D., La Mantia L., Rigamonti A., Usai S., Mascoli N., Milanese C., and Bussone Gl. Prevalence of primary headaches in people with multiple sclerosis. Cephalalgia 24 (2004) 980-984
24. Detry-Morel M., Boschi A., Gehenot M., and Geubel A. Bilateral transient visual obscurations with headache during alpha-II interferon therapy: A case report. Eur. J. Ophthalmol. 5 (1995) 271-274
25. Di Rosa G., Spanò M., Pustorino G., Ferrari M.D., Stam A.H., Sgrò D.L., Mannarino E., Bonsignore M., and Tortorella G. Alternating hemiplegia of childhood successfully treated with topiramate: 18 months of follow-up. Neurology 66 (2006) 146
26. Eggers S.D. Migraine-related vertigo: Diagnosis and treatment. Curr. Neurol. Neurosci. Rep. 6 (2006) 106-115
27. Ehde D.M., Osborne T.L., and Jensen M.P. Chronic pain in persons with multiple sclerosis. Phys. Med. Rehabil. Clin. N. Am. 16 (2005) 503-512
28. Empl M., Sostak P., Riedel M., Schwarz M., Muller N., Forderreuther S., and Straube A. Decreased sTNF-RI in migraine patients?. Cephalalgia 23 (2003) 55-58
29. Evans R.W., and Rolak L.A. Migraine versus multiple sclerosis. Headache 41 (2001) 97-98
30. Evans R.W., and Rolak L.A. The Alice in Wonderland syndrome. Headache 44 (2004) 624-625
31. Ferrari M.D. Migraine. Lancet 351 (1998) 1043-1051
32. Ferreira S., D'Cruz D.P., and Hughes G.R. Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: Where do we stand?. Rheumatology 44 (2005) 434-442
33. Fidan I., Yüksel S., Ýmir T., Irkeç C., and Nur Aksakal F. The importance of cytokines, chemokines and nitric oxide in pathophysiology of migraine. J. Neuroimmunol. 171 (2006) 184-188
34. Freedman M.S., and Gray T.A. Vascular headache: A presenting symptom of multiple sclerosis. Can. J. Neurol. Sci. 16 (1989) 63-66
35. Freedom T., and Jay W.M. Migraine with and without headache. Semin. Ophthalmol. 18 (2003) 210-217
36. Galetta S.L., and Markowitz C. US FDA-approved disease-modifying treatments for multiple sclerosis. Review of adverse effect profiles. CNS drugs 19 (2005) 239-252
37. Gee J.R., Chang J., Dublin A.B., and Vijayan N. The association of brainstem lesions with migraine-like headache: An imaging study of multiple sclerosis. Headache 45 (2005) 670-677
38. Ghezzi A. Immunomodulatory treatment of early onset multiple sclerosis: Results of an Italian co-operative study. Neurol. Sci. 26 Suppl. 4 (2005) S183-S186
39. Gold R., Rieckmann P., Chang P., Abdalla J., and PRISMS Study Group. The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study. Eur. J. Neurol. 12 (2005) 649-656
40. Gupta G., Gelfand J.M., and Lewis J.D. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 129 (2005) 819-826
41. Haas D.C., Kent P.F., and Friedman D.I. Headache caused by a single lesion of multiple sclerosis in the peri-aqueductal gray area. Headache 33 (1993) 452-455
42. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. 1st ed. Cephalalgia 8 Suppl. 7 (1988) 9-96 1st ed
43. Headache Classification Subcommittee of the International Headache Society. Classification and WHO ICD-10 codes-IHS ICHD-II. Cephalagia 24 Suppl. 1 (2004) S1-S16
44. Headache Classification Committee of the International Headache Society. The international classification of headache disorders. Cephalalgia 24 (2004) 1-159 2nd ed
45. Hughes G.R.V. Migraine, memory loss, and "multiple sclerosis." Neurologic features of the antiphospholipid (Hughes') syndrome. Postgrad. Med. J. 79 (2003) 81-83
46. Jacobi C., Stingele K., Kretz R., Hartmann M., Storch-Hagenlocher B., Breitbart A., and Wildemann B. Neuromyelitis optica (Devic's syndrome) as first manifestation of systemic lupus erythematosis. Lupus 15 (2006) 107-109
47. Jacome D.E., and Leborgne J. MRI studies in basilar artery migraine. Headache 30 (1990) 88-90
48. Jen J.C., Kim G.W., Dudding K.A., and Baloh R.W. No mutations in CACNA1A and ATP1A2 in probands with common types of migraine. Arch. Neurol. 61 (2004) 926-928
49. Kantarci O., and Wingerchuk D. Epidemiology and natural history of multiple sclerosis: New insights. Curr. Opin. Neurol. 19 (2006) 248-254
50. Kimper-Karl A.C., Jensen H.B., and Kristensen O. CADASIL versus multiple sclerosis. Ugeskr. Laeger. 168 (2006) 702-703
51. Kirchmann M. Migraine with aura: New understanding from clinical epidemiologic studies. Curr. Opin. Neurol. 19 (2006) 286-293
52. Kirchmann M., Thomsen L.L., and Olesen J. The CACNA1A and ATP1A2 genes are not involved in dominantly inherited migraine with aura. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141 (2006) 250-256
53. Kirchmann Eriksen M., Thomsen L.L., and Olesen J. Implications of clinical subtypes of migraine with aura. Headache 46 (2006) 286-297
54. Kitigawa Y. Neurological aspects in antiphospholipid syndrome. Rinsho Shinkeigaku 43 (2003) 744-747
55. Khromov A., Segal M., Nissinoff J., and Fast A. Migraines linked to interferon-β treatment of multiple sclerosis. Am. J. Phys. Med. Rehabil. 84 (2005) 644-647
56. Knight Y.E., and Goadsby P.J. The peri-aqueductal grey matter modulates trigeminovascular input: A role in migraine?. Neuroscience 106 (2001) 793-800
57. Koch-Henriksen N., Sørensen P.S., Christensen T., Frederiksen J., Ravnborg M., Jensen K., Heltberg A., Kristensen O., Stenager E., Petersen T., and Hansen T. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 66 (2006) 1056-1060
58. Kruit M.C., van Buchem M.A., Hofman P.A., Bakkers J.T., Terwindt G.M., Ferrari M.D., and Launer L.J. Migraine as a risk factor for subclinical brain lesions. JAMA 291 (2004) 427-434
59. Kruit M.C., Launer L.J., Ferrari M.D., and van Buchem M.A. Infarcts in the posterior circulation territory in migraine. The population-based MRI CAMERA study. Brain 128 (2005) 2068-2077
60. Kruit M.C., Launer L.J., Ferrari M.D., and van Buchem M.A. Brain stem and cerebellar hyperintense lesions in migraine. Stroke 37 (2006) 1109-1112
61. La Mantia L., and Erbetta A. Headache and inflammatory disorders of the central nervous system. Neurol. Sci. 25 Suppl. 3 (2004) S148-S153
62. Lauer K. Divergent risk of multiple sclerosis in two Anabaptist communities in America. Med. Hypotheses 67 (2006) 969-974
63. Leavell R., Ray C.G., Ferry P.C., and Minnich L.L. Unusual acute neurologic presentations with Epstein-Barr virus infection. Arch. Neurol. 43 (1986) 186-188
64. β-1a therapy and during its ongoing use for relapsing-remitting multiple sclerosis. Mult. Scler. 10 (2004) 636-642
65. Levin N., Mor M., and Ben-Hur T. Patterns of misdiagnosis of multiple sclerosis. Isr. Med. Assoc. J. 5 (2003) 489-490
66. Lips P. Vitamin D physiology. Prog. Biophys. Mol. Biol. 92 (2006) 4-8
67. Longoni M., and Ferrarese C. Inflammation and excitotoxicity: Role in migraine pathogenesis. Neurol. Sci. 27 Suppl. 2 (2006) S107-S110
68. Mack K.J. What incites new daily persistent headache in children?. Pediatr. Neurol. 31 (2004) 122-125
69. Marangoni S., Argentiero V., and Tavolato B. Neurosarcoidosis: Clinical description of 7 cases with a proposal for a new diagnostic strategy. J. Neurol. 253 (2006) 488-495
70. Mark B.L., and Carson J.A. Vitamin D and autoimmune disease-implications for practice from the multiple sclerosis literature. J. Am. Diet. Assoc. 106 (2006) 418-424
71. Martinez Sobrepera H.J., Cabrera Gomez J.A., and Tuero Iglesias A. Exogenous factors in the aetiology of multiple sclerosis in Cuba. A study of cases and controls. Rev. Neurol. 33 (2001) 931-937
72. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50 (2001) 121-127
73. Minagar A., and Sheremata W.A. Glossopharyngeal neuralgia and MS. Neurology 54 (2000) 1368-1370
74. Minagar A., Gonzalez-Toledo E., Pinkston J., and Jaffe S.L. Neuroimaging in multiple sclerosis. Int. Rev. Neurobiol. 67 (2005) 165-201
75. Mohr D.C., Hart S.L., and Goldberg A. Effects of treatment for depression on fatigue in multiple sclerosis. Psychosom. Med. 65 (2003) 542-547
76. Moja P.L., Cusi C., Sterzi R.R., and Canepari C. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst. Rev. 3 (2005) CD002919
77. Monaca-Charley C., Stojkovic T., Duhamel A., De Seze J., Ferriby D., and Vermersch P. Double-blind crossover study with dolasetron mesilate, a 5-HT3 receptor antagonist in cerebellar syndrome secondary to multiple sclerosis. J. Neurol. 250 (2003) 1190-1194
78. Moskowitz M.A., and Cutrer F.M. Sumatriptan: A receptor-targeted treatment for migraine. Ann. Rev. Med. 44 (1993) 145-154
79. Mueller L., Gupta A.K., and Stein T.P. Deficiency of tumor necrosis factor alpha in a subclass of menstrual migraineurs. Headache 41 (2001) 129-137
80. Neilley L.K., Goodin D.S., Goodkin D.E., and Hauser S.L. Side effect profile of interferon beta-1b in MS: Results of an open label trial. Neurology 46 (1996) 552-554
81. Nortvedt M.W., Riise T., Myhr K.M., Nyland H.I., and Hanestad B.R. Type I interferons and the quality of life of multiple sclerosis patients. Results from a clinical trial on interferon alfa-2a. Mult. Scler. 5 (1999) 317-322
82. Nortvedt M.W., Riise T., and Maeland J.G. Multiple sclerosis and lifestyle factors: The Hordaland health study. Neurol. Sci. 26 (2005) 334-339
83. Oka T., Oka K., Hosoi M., and Hori T. Intracerebroventricular injection of interleukin-6 induces thermal hyperalgesia in rats. Brain Res. 692 (1995) 123-128
84. Ordonez L., Skromne E., Ontaneda D., and Rivera V.M. Multiphasic disseminated encephalomyelitis, systemic lupus erythematosus and antiphospholipid syndrome. Clin. Neurol. Neurosurg. 109 (2007) 102-105
85. Österberg A., Boivie J., and Thuomas K.-A. Central pain in multiple-prevalence and clinical characteristics. Eur. J. Pain 9 (2004) 531-542
86. Perez-Cesari C., Saniger M.M., and Sotelo J. Frequent association of multiple sclerosis with varicella and zoster. Acta Neurol. Scand. 112 (2005) 417-419
87. Pöllmann W., Erasmus L.-P., Feneberg W., Then Bergh F., and Straube A. Interferon beta but not glatiramer acetate therapy aggravates headaches in MS. Neurology 59 (2002) 636-639
88. Pöllmann W., Feneberg W., and Erasmus L.-P. Pain in multiple sclerosis-a still underestimated problem. The 1 year prevalence of pain syndromes, significance and quality of care of multiple sclerosis inpatients. Nervenarzt 75 (2004) 135-140
89. Pöllmann W., Erasmus L.-P., Feneberg W., and Straube A. The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS. Neurology 66 (2006) 275-277
90. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.-P., Kappos L., Lublin F.D., Metz L.M., McFarland H.F., O'Connor P.W., Sandberg-Wollheim M., Thompson A.J., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria.". Ann. Neurol. 58 (2005) 840-846
91. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., Phillips J.T., Lublin F.D., Giovannoni G., Wajgt A., Toal M., Lynn F., et al., AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354 (2006) 899-910
92. Poser C.M. The multiple sclerosis trait and the development of multiple sclerosis: Genetic vulnerability and environmental effect. Clin. Neurol. Neurosurg. 108 (2006) 227-233
93. Poser C.M., Presthus J., and Horsda O. Clinical characteristics of autopsy-proven multiple sclerosis. Neurology 16 (1966) 791-798
94. Prat E., Tomaru U., Sabater L., Park D.M., Granger R., Kruse N., Ohayon J.M., Bettinoti M.P., and Martin R. HLA-DRB5*0101 and -DRB1*1501 expression in the multiple sclerosis-associated HLA-DR15 haplotype. J. Neuroimmunol. 167 (2005) 108-119
95. Rainero I., Fasano E., Rubino E., Rivoiro C., Valfre W., Gallone S., Savi L., Gentile S., Lo Giudice R., De Martino P., Dall'Omo A.M., and Pinessi L. Association between migraine and HLA-DRB1 gene polymorphisms. J. Headache Pain 6 (2005) 185-187
96. Rainero I., Dall'Omo A.M., Rubino E., Valfre W., Fasano M.E., Rivoiro C., Brancatello F., Savi L., Gallone S., and Pinessi L. HLA-DRB1 genotyping in Italian migraine patients. Neurosci. Lett. 393 (2006) 90-93
97. Reess J., Haas J., Gabriel K., Fuhlrott A., and Fiola M. Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (Avonex®) therapy. Mult. Scler. 8 (2002) 15-18
98. Rinalduzzi S., Valeriani M., and Vigevano F. Brainstem dysfunction in alternating hemiplegia of childhood: A neurophysiological study. Cephalalgia 26 (2006) 511-519
99. Resnick S., Reyes-Iglesias Y., Carreras R., and Villalobos E. Migraine with aura associated with reversible MRI abnormalities. Neurology 66 (2006) 946-947
100. Rice G.P., Lesaux J., Vandervoort P., Macewan L., and Ebers G.C. Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor. J. Neurol. Neurosurg. Psychiatry 62 (1997) 282-284
101. Rickards H. Depression in neurological disorders: Parkinson's disease, multiple sclerosis, and stroke. J. Neurol. Neurosurg. Psychiatry 76 Suppl. I (2005) i48-i52
102. Río J., Nos C., Bonaventura I., Arroyo R., Genis D., Sureda B., Ara J.R., Brieva L., Martín J., Saiz A., Sánchez López, Prieto J.M., et al. Corticosteroids, ibuprofen, and acetaminophen for IFNβ-1a flu symptoms in MS. Neurology 63 (2004) 525-528
103. Rocca M.A., Ceccarelli A., Falini A., Tortorella P., Colombo B., Pagani E., Comi G., Scotti G., and Filippi M. Diffusion tensor magnetic resonance imaging at 3.0 tesla shows subtle cerebral grey matter abnormalities in patients with migraine. J. Neurol. Neurosurg. Psychiatry 77 (2006) 686-689
104. Rocca M.A., Ceccarelli A., Falini A., Colombo B., Tortorella P., Bernasconi L., Comi G., Scotti G., and Filippi M. Brain gray matter changes in migraine patients with T2-visible lesions. A 3-T MRI study. Stroke 37 7 (2006) 1765-1770
105. Rolak L.A., and Brown S. Headaches and multiple sclerosis: A clinical study and review of the literature. J. Neurol. 237 (1990) 300-302
106. Rovaris M., Bozzali M., Rocca M.A., Colombo B., and Filippi M. An MR study of tissue damage in the cervical cord of patients with migraine. J. Neurol. Sci. 183 (2001) 43-46
107. Russell M.B., and Olesen J. Increased familial risk and evidence of genetic factor in migraine. BMJ 311 (1995) 541-544
108. Sandyk R., and Awerbuch G.I. The co-occurrence of multiple sclerosis and migraine headache: The serotoninergic link. Int. J. Neurosci. 76 (1994) 249-257
109. Sarchielli P., Alberti A., Baldi A., Coppola F., Rossi C., Pierguidi L., Floridi A., and Calabresi P. Proinflammatory cytokines, adhesion molecules, and lymphocyte integrin expression in the internal jugular blood of migraine patients without aura assessed ictally. Headache 46 (2006) 200-207
110. Shevell M.I. Acephalgic migraine of childhood. Pediatr. Neurol. 14 (1996) 211-215
111. Silberstein S.D., Lipton R.B., and Goadsby P.J. Migraine: Diagnosis and treatment. "Headache in Clinical Practice,". 2nd ed. (2002), Martin Dunitz Ltd., London, United Kingdom 76
112. Smith K.J., and McDonald W.I. The pathophysiology of multiple sclerosis: The mechanisms underlying the production of symptoms and the natural history of the disease. Phil. Trans. R. Soc. Lond. B 354 (1999) 1649-1673
113. Solaro C., Lunardi G.L., and Mancarki G.L. Pain and MS. Int. MS J. 10 (2003) 14-19
114. Stewart W.F., Bigal M.E., Kolodner K., Dowson A., Liberman J.N., and Lipton R.B. Familial risk of migraine: Variation by proband age at onset and headache severity. Neurology 66 (2006) 344-348
115. Takeshima T., Ishizaki K., Fukuhara Y., Ijiri T., Kusumi M., Wakutani Y., Mori M., Kawashima M., Kowa H., Adachi Y., Urakami K., and Nakashima K. Population-based door-to-door survey of migraine in Japan: The Daisen study. Headache 44 (2004) 8-19
116. Tepper S.J., Rapoport A., and Sheftell F. The pathophysiology of migraine. Neurologist 7 (2001) 279-286
117. Thacker E.L., Mirzaei F., and Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: A meta-analysis. Ann. Neurol. 59 (2006) 499-503
118. Thomsen L.L., and Olesen J. Sporadic hemiplegic migraine. Cephalagia 24 (2004) 1016-1023
119. Thys-Jacobs S. Vitamin D and calcium in menstrual migraine. Headache 34 (1994) 544-546
120. Thys-Jacobs S. Alleviation of migraines with therapeutic vitamin D and calcium. Headache 34 (1994) 590-592
121. Tortorella P., Rocca M.A., Colombo B., Annovazzi P., Comi G., and Filippi M. Assessment of MRI abnormalities of the brainstem from patients with migraine and multiple sclerosis. J. Neurol. Sci. 244 (2006) 137-141
122. Trojano M., and Paolicelli D. The differential diagnosis of multiple sclerosis: Classification and clinical features of relapsing and progressive neurological syndromes. Neurol. Sci. 22 Suppl. 2 (2001) S98-S102
123. Walther E.U., and Hohlfeld R. Multiple sclerosis. Side effects of interferon beta therapy and their management. Neurology 53 (1999) 1622-1627
124. Warren S., and Warren K.G. Multiple sclerosis and associated diseases: A relationship to diabetes mellitus. Can. J. Neurol. Sci. 8 (1981) 35-39
125. Watkins M.S., and Espir M. Migraine and multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 32 (1969) 35-37
126. Welch K.M., Nagesh V., Aurora S.K., and Gelman N. Periaqueductal gray matter dysfunction in migraine: Cause or the burden of illness?. Headache 41 (2001) 629-637
127. Young A.C. Misdiagnosis of MS. Lancet 350 (1997) 522
128. Zakrzewska J.M. Diagnosis and differential diagnosis of trigeminal neuralgia. Clin. J. Pain 18 (2002) 14-21
129. Zeinstra E.M., Wilczak N., Wilschut J.C., Glazenburg L., Chesik D., Kroese F.G., and De Keyser J. 5HT(4) agonists inhibit interferon-gamma-induced MHC class II and B7 costimulatory molecules expression on cultured astrocytes. J. Neuroimmunol. 179 (2006) 191-195
130. Zorzon M., Zivadinov R., Nasuelli D., Dolfini P., Bosco A., Bratina A., Tommasi M.A., Locatelli L., and Cazzato G. Risk factors of multiple sclerosis: A case-control study. Neurol. Sci. 24 (2003) 242-247